{"id":"insulin-viaject-75","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VIAject uses Biodel's proprietary formulation technology to accelerate insulin absorption from subcutaneous injection sites, achieving faster peak serum levels compared to conventional insulin. This faster pharmacokinetic profile aims to more closely mimic the body's natural insulin secretion pattern in response to meals, potentially improving glycemic control and reducing hypoglycemic episodes.","oneSentence":"Insulin VIAject is a rapid-acting insulin formulation designed to be absorbed faster than standard insulin injections, allowing for quicker onset of action and better postprandial glucose control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:25.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04663295","phase":"NA","title":"MiniMed™ 670G System China Study for Type I Diabetic","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2020-10-31","conditions":"Diabetes Mellitus, Type 1","enrollment":74},{"nctId":"NCT02324309","phase":"PHASE1, PHASE2","title":"BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-05","conditions":"Diabetes Mellitus","enrollment":12},{"nctId":"NCT00849576","phase":"PHASE3","title":"Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Biodel","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin VIAject™ (75%)","genericName":"Insulin VIAject™ (75%)","companyName":"Biodel","companyId":"biodel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin VIAject is a rapid-acting insulin formulation designed to be absorbed faster than standard insulin injections, allowing for quicker onset of action and better postprandial glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}